

Personalized Stem Cells Announces All Data Collected from FDA Approved Stem Cell Clinical Trial for Knee Arthritis

Personalized Stem Cells, Inc. announces the final data has been collected for their FDA approved stem cell clinical trial for knee osteoarthritis.

POWAY, CALIFORNIA, US, January 12, 2021 /EINPresswire.com/ -- [Personalized Stem Cells, Inc](#)



We are optimistic that the data obtained from the Phase 1 study will demonstrate the relative safety of autologous stem cell therapy for knee osteoarthritis..."

Dr. Bob Harman, CEO

(PSC), an adipose-derived stem cell company, announces that the data collection process is complete for their Phase I FDA approved stem cell clinical trial for the treatment of knee osteoarthritis. In early October 2020, the company [announced](#) that the last clinical trial participant received treatment with their own stem cells. The final data collection point came in late December 2020.

Now that data collection is complete, PSC will begin the process of compiling and analyzing the data prior to FDA submission. Stem cell therapies/products are regulated by

the FDA and must undergo a thorough approval process to assess safety and efficacy for the intended population.


PSC founder and CEO, Dr. Bob Harman, stated, "Despite the challenges resulting from a global pandemic, we are proud to have reached this milestone in our first FDA approved clinical trial. We are optimistic that the data obtained from the Phase 1 study will demonstrate the relative safety of autologous stem cell therapy for knee osteoarthritis, and we look forward to presenting this data to the FDA." PSC aims to compile and submit clinical study data to the FDA by the end of the quarter, after which a Phase 2 blinded, placebo-controlled study will be next. While Phase 1 studies focus on safety, the emphasis of Phase 2 studies is on effectiveness.

In addition to a Phase 2 knee trial, PSC plans to pursue FDA approval for a stem cell clinical trial to treat traumatic brain injury (concussion) in 2021. Stem cell therapy may provide answers and tools to address the chronic debilitation experienced by TBI victims. Recent studies have found that stem cells have demonstrated the ability to regenerate damaged nerve tissues which may lead to an improvement in disabilities and thereby quality of life.

[About Personalized Stem Cells, Inc.](#)

Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by securing FDA approval for autologous stem cells for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego (California), is conducting clinical trials and developing stem cell products in the areas of orthopedics, pain, and traumatic brain injury. PSC has licensed a portfolio of patents and applications in the field of regenerative medicine which includes patent applications covering treatment of lung diseases including COVID-19.

Michael Dale, President/COO
Personalized Stem Cells, Inc
+1 833-772-3557
[email us here](#)



This press release can be viewed online at: <https://www.einpresswire.com/article/534355406>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.